Skip to main content
  • About
  • News & Events
  • Careers
  • Contact
  • Subscribe
FR
Canada’s Drug Agency | Drugs, Health Technologies and Systems.
  • Find Reports
    • Programs & Initiatives
      • Appropriate Use
      • Canadian Medical Imaging Inventory
      • Drugs for Rare Diseases
      • Health Systems
      • Health Technology Reviews
      • Horizon Scans
      • Post-Market Drug Evaluation
      • Reimbursement Reviews
      • Scientific Advice
    • Methods
      • Conflict of Interest
      • Methodological Guidelines
      • Program Procedures
    • Tools & Publications
      • Common Acronyms
      • Evidence Bundles
      • HTA Excel Tools
      • Finding the Evidence: Literature Searching Tools in Support of Systematic Reviews
      • Canadian Journal of Health Technologies
    • Provide Input
      • Current Opportunities
      • Instructions
      • Procedures & Templates
    • Engage
      • Sponsor a Reimbursement Review
      • Request Scientific Advice
      • Request an Evidence Review
    • Community Involvement
      • Collaboration and Outreach
      • Patient Groups
      • Pan-Canadian Collaborative
Canada’s Drug Agency | Drugs, Health Technologies and Systems.
FR
  • Find Reports
  • Our Work
    • Programs & Initiatives
      • Advisory Panel: Pan-Canadian Prescription Drug List
      • Appropriate Use
      • Canadian Medical Imaging Inventory
      • Drugs for Rare Diseases
      • Health Systems
      • Health Technology Reviews
      • Horizon Scans
      • Post-Market Drug Evaluation
      • Reimbursement Reviews
      • Scientific Advice
    • Methods
      • Conflict of Interest
      • Methodological Guidelines
      • Program Procedures
    • Tools & Publications
      • Common Acronyms
      • Evidence Bundles
      • HTA Excel Tools
      • Finding the Evidence: Literature Searching Tools in Support of Systematic Reviews
      • Canadian Journal of Health Technologies
  • Get Involved
    • Provide Input
      • Current Opportunities
      • Instructions
      • Procedures & Templates
    • Engage
      • Sponsor a Reimbursement Review
      • Request Scientific Advice
      • Request an Evidence Review
    • Community Involvement
      • Collaboration and Outreach
      • Patient Groups
      • Pan-Canadian Collaborative
  • About
  • News & Events
  • Careers
  • Contact
  • Subscribe

Adult classical Hodgkin lymphoma

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs

Details

Review Type: Rapid

Provisional Funding Algorithm

Scoping Posted : 17-Jul-25
Input Deadline : 08-Sept-25
Last Updated : July 17, 2025

Unresectable hepatocellular carcinoma - Input Submission - Provisional Funding Algorithm - Proposed Scope

Unresectable hepatocellular carcinoma

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs

Details

Review Type: Rapid

Provisional Funding Algorithm

Scoping Posted : 17-Jul-25
Input Deadline : 08-Sept-25
Last Updated : July 17, 2025

Breast Cancer with inclusion of HER2 Low or HER2 Ultra Low - Proposed Scope

Breast Cancer with inclusion of HER2 Low or HER2 Ultra Low

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs

Details

Review Type: Rapid

Provisional Funding Algorithm

Scoping Posted : 17-Jul-25
Input Deadline : 08-Sept-25
Last Updated : July 17, 2025

blinatumomab and dasatinib

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs

Details

Last Updated : July 16, 2025

palopegteriparatide

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs

Details

Last Updated : July 15, 2025

avacincaptad pegol

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs

Details

Last Updated : July 10, 2025

bevacizumab

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs

Details

Last Updated : July 9, 2025

encorafenib

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs

Details

Last Updated : July 9, 2025

Pagination

  • Previous page ‹‹
  • Page 2
  • Next page ››

Canada’s Drug Agency is a pan-Canadian health organization, created and funded by Canada’s federal, provincial, and territorial governments.

We provide Canada’s health system leaders with independent evidence and advice so they can make informed drug, health technology, and health system decisions, and we collaborate with national and international partners to enhance our collective impact. 

  • Reports
  • Contact
  • Careers
  • Help

Stay up to date on the latest from Canada’s Drug Agency by subscribing to our newsletter.

Already subscribed? Update your preferences.

  • visit us on facebook
  • visit us on linkedin
  • visit us on youtube
  • visit us on instagram

© 2025 Canadian Agency for Drugs and Technologies in Health

  • Privacy Policy
  • Terms of Use
  • Accessibility
  • Request for Archived Report
Back to Top